Eli Lilly Shares Could Be Set for a Big Move if the Zepbound Maker Adds to Its Winning Streak

Eli Lilly and Company (LLY) shares have been on a tear lately, and there are no signs of slowing down. The stock has gained more than 20% in the past year, and it is now trading at its highest level since 2009.

There are a number of factors that are driving Lilly's recent success. One of the most important is the company's strong pipeline of new drugs. Lilly has several promising drugs in late-stage development, including treatments for cancer, diabetes, and Alzheimer's disease.

Another factor that is driving Lilly's share price higher is the company's strong financial performance. Lilly has consistently beaten Wall Street estimates for earnings and revenue, and the company has a strong balance sheet. This financial strength gives Lilly the flexibility to invest in its pipeline and to make acquisitions.

In addition to its strong pipeline and financial performance, Lilly is also benefiting from a number of tailwinds in the healthcare industry. These include the aging population, which is creating a greater demand for healthcare products and services, and the increasing prevalence of chronic diseases, such as cancer and diabetes.

Overall, Lilly is a well-positioned company with a strong pipeline, a strong financial position, and a number of tailwinds in the healthcare industry. The company's shares are likely to continue to perform well in the future, and investors should consider buying Lilly shares if they are looking for a long-term investment.